Results 71 to 80 of about 4,156,285 (177)
Annals of Gastroenterological Surgery, Volume 10, Issue 3, Page 871-882, May 2026.In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura +9 more
wiley +1 more source
PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection
, 2007 OBJECTIVES: The aim of this study is to assess the usefulness of prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) in monitoring of recurrent hepatocellular carcinoma (HCC) after curative resection.
안상훈 +8 more
core +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye +9 more
wiley +1 more source
Validation of a novel model for the early detection of hepatocellular carcinoma
Clinical Proteomics, 2019 Background The biomarkers alpha-fetoprotein (AFP) and protein induced by vitamin K absence/antagonist-II (PIVKA-II) may be useful for detecting early-stage hepatocellular carcinoma (HCC). We evaluated the performance of AFP and PIVKA-II levels, alone and
Philip M. Hemken +11 more
doaj +1 more source
Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.Three hypermethylated cfDNA markers specific to liver cancer, RNF135, CHFR and PAX5, were identified in peripheral blood and used to construct a diagnostic model. The model achieved 94.43% sensitivity and 95.16% specificity in a large clinical validation cohort, with a sensitivity of 93.1% for stage‐I liver cancer. Abstract Background and aims Existing
Ruohan Zhang +23 more
wiley +1 more source
Rare Metals, Volume 45, Issue 5, May 2026.ABSTRACT Early diagnosis of liver cancer demands high sensitivity, high specificity, convenience and real‐time monitoring capabilities. However, it encounters challenges such as low concentration of markers, numerous interfering factors, and limitations of detection technologies.
Changsheng Shi +10 more
wiley +1 more source
Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study [PDF]
, 2019 Introduction: Protein induced by vitamin K absence II (PIVKA-II) is an abnormal prothrombin increased in gastrointestinal malignancy. We aimed to evaluate PIVKA-II in comparison to established pancreatic cancer (PC) biomarkers (CA 19-9, carcinoembryonic ...
Granato, Teresa +17 more
core +1 more source
Infectious Agents and Cancer, 2019 Aim To evaluate the correlation of serum PIVKA-II levels and development of portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) patients.
Tao Li +10 more
doaj +1 more source
Hepatology Research, Volume 56, Issue 5, Page 853-860, May 2026.ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida +11 more
wiley +1 more source
, 1995 Protein induced by vitamin K absence or antagonist II(PIVKA-II) is a diagnostic marker of hepatocelllar carcinoma(HCC0 that has attracted a significant attraction for its high specificity compared to AFP. (Objectives) This study was conducted to evaluate
김, 동우 +5 more
core